secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2025-05-22T23:59:59+00:00
Accession:  0000914475-25-000120
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine holds 2025 annual meeting; shareholders approve new equity plan and amended ESPP
--------------------------------------------------------------------------------

- Four Class II directors elected for three-year terms expiring 2028: Kyle Gano, Richard Pops, Shalini Sharp, Stephen Sherwin (each >72M votes).
- Advisory say-on-pay approved: ~78M for, ~6M against, ~1.7M abstentions.
- 2025 Equity Incentive Plan approved: ~72.6M for, ~12.9M against.
- Amended and Restated 2018 ESPP approved: ~85.4M for, ~138K against.
- Ratification of Ernst & Young as independent auditor for FY2025 approved: ~85M for, ~5.2M against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447525000120/0000914475-25-000120-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447525000120/nbix-20250521.htm
  HTML page:      https://secwatch.observer/filing/0000914475-25-000120

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer